Furthermore, GEP data from untreated and Imatinib-treated bone marrow cells of CML patients [10] showed that inhibition of BCR-ABL significantly reduces DNMT1 expression (T test P value = 0.0004; Fig. 1c). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.